cally identified plasma cells in the peripheral blood. The patient was examined further and the diagnosis of multiple myeloma was established in November 1995. The paraproWe describe a patient with multiple myeloma who was treated with intensive therapy and autologous blood cell tein was IgG-kappa (31.5 g/l). Bone marrow aspiration showed 90% infiltration with plasma cells with atypical transplantation as her first-line treatment. The disease relapsed 3 months after the transplant as plasma cell morphology. There were several osteolytic bone lesions in the thoracic spine and ribs. The concentrations of serum leukemia and the patient succumbed in 4 weeks. We suggest that an aggressive plasma cell clone may be calcium and creatinine were normal. The disease was staged III A because of the anemia and bone lesions. selected during the course of intensive treatment. Complex karyotypic findings are also presented.
6
/kg CD34 + cells) 3 months after the diagnosis. Intensified first-line treatment with autologous stem cell
After an additional VAD course the patient was found rescue has been shown to improve survival in multiple to be in clinical remission: less than 5% plasma cells in myeloma in comparison to conventional chemotherapy. 1 bone marrow, and serum IgG concentration 8.6 g/l. She However, until now no patient has been reported to be underwent a high-dose treatment with melphalan cured of his/her disease and relapses occur after a median 140 mg/m 2 and 12 Gy total body irradiation in five fracof 2.5 years post-transplant.
2 Some patients may relapse tions. Stem cells were reinfused in March 1996. She recoquite soon after the intensive treatment which raises the vered well, blood neutrophils reached a level Ͼ1 × 10 9 /l on question about a possible survival and proliferative advanday +11 and platelets Ͼ20 × 10 9 /l on day +10, and she was tage of the most aggressive myeloma cell clone. Supporting discharged on day +13 post-transplant. this view we report a patient with multiple myeloma who In July 1996, 3 months after ABCT, the patient was underwent intensive therapy with autologous blood cell examined because of nausea, general malaise and leg pains. transplantation (ABCT) as her first-line therapy and who Blood Hb concentration was 124 g/l, platelets 23 × 10 9 /l relapsed in plasma cell leukemic phase 3 months post-transand WBC 14.6 × 10 9 /l of which 35% were plasma cells. plant.
Serum creatinine concentration was 198 mol/l (normal Ͻ100 mol/l), serum total calcium concentration 4.61 mmol/l (Ͻ2.47), and ionized calcium 2.52 mmol/l (Ͻ1.32).
Case report
Serum lactate dehydrogenase was 5085 U/l (Ͻ450), IgG 25.6 g/l (Ͻ15), ␤ 2 -microglobulin 8.8 mg/l (Ͻ2.4), and urate The patient was a 42-year-old female, previously in good 886 mol/l (Ͻ340). Serum C-reactive protein was normal physical health. She had a prolonged respiratory tract infec-(Ͻ10 mg/l). There was progression in osteolytic bone tion and myalgias in autumn 1995. Routine laboratory tests lesions. Ultrasonography showed liver infiltrate, and pararevealed anemia, blood hemoglobin (Hb) concentration was aortic lymph node enlargement was seen by nuclear mag-88 g/l, and erythrocyte sedimentation rate was raised to netic imaging. More than 95% of bone marrow was infil-140 mm/h. White blood cell count (WBC) was 9.6 × 10 9 /l trated by anaplastic pleomorphic plasma cells. Bone marwith normal differential count and without any morphologirow and peripheral blood cell immunophenotyping showed 81% and 72% B-B4 + , and 91% and 22% CD38 bright+ cells, respectively, which is consistent with plasma cell mor- (1)(p32),der(1;19) myeloma cells, purification of the blood grafts with stem (q10;p10), add(2)(p21),−4, add(4)(qter), del(6)(q23), der (9) cell (CD34 cell) selection has been introduced. 6 t(1;9) (q21; p24), del(12) (p13), ins (13;?) (q21?), +?del(13) Our patient relapsed exceptionally early after intensive (q?14q?32),−14,−15,−21. Complete karyotype of the hypertreatment with ABCT rescue. In the retrospective series of triploid clone is shown in Figure 1. the EBMT, the median duration of relapse-free survival for The patient was treated with the VAD regimen but no patients in complete remission post-transplant was 29 response was achieved. She had severe infection and genmonths. 2 In some patients, response duration was very short eralized hemorrhagic diathesis and died 30 days after diagwhich has raised the possibility that high-dose treatment nosis in relapse. In autopsy massive gastrointestinal bleedselects a resistant cell clone with high proliferative capacity ing was detected. Microscopic analysis showed plasma cell and unopposed growth pattern. In our case, this clone had infiltrates in lymph capillaries, kidneys, liver, spleen, bone the characteristics of plasma cell leukemia. marrow and dura mater. Lymph node enlargement was
The modal chromosome numbers seen in the two clones not seen.
are in agreement with the flow cytometric DNA analysis. In vitro culture of mononuclear cells from the relapsed Abnormalities of chromosome 1, and deletions of chromomarrow was undertaken. At present, spontaneous in vitro somes 6 and 13 are frequent findings in multiple myeloma growth of clonal lymphoblastoid cells has been continuing but no chromosome abnormality has been demonstrated to for more than 10 months.
be specific or consistent in plasma cell disorders or plasma cell leukemia. 7 Plasma cells have low proliferative capacity, and preDiscussion viously human myeloma cell lines could only be established from cells originating in extramedullary plasmaIntensive treatment of multiple myeloma with allogeneic or autologous stem cell rescue has introduced a few durable cytomas, pleural fluid or plasma cell leukemias. 8 Also, in Figure 1 Karyotype of the hypertriploid bone marrow cell from a patient with plasma cell leukemia. The abnormal clone is: 71,XX,−X, der (1;19)(q10;p10), +der(1;19)(q10;p10), add(2)(p21), add(2)(p21), −4, del(6)(q23), +del(6)(q23),+7,+8, der(9)t(1;9)(q21;p24), der (9) highly resistant myeloma cell clone may be spared by inten-
